Cytex Therapeutics Inc is categorized under Research and Development Laboratories in Durham, NC and active since 2006.
Cytex Therapeutics Inc was established in 2006, and today employs 1 to 4, earning $0 to $49.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Farshid Guilak at the company’s single location by writing to 2608 Erwin Road # 19a, Durham, North Carolina NC 27705 or by phoning (919) 912-9837. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Cytex Therapeutics Inc |
| Contact Person: | Farshid Guilak |
| Address: | 2608 Erwin Road # 19a, Durham, North Carolina 27705 |
| Phone Number: | (919) 912-9837 |
| Annual Revenue (USD): | $0 to $49.999 |
| Founded: | 2006 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Cytex Therapeutics Inc was started in 2006 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $0 to $49.999 per annum.
Feel free to contact Farshid Guilak for inquiries that concern Cytex Therapeutics Inc by calling the company number (919) 912-9837, as your correspondence is most welcome. Additionally, the physical location of the single location of Cytex Therapeutics Inc can be found at the coordinates 36.00885,-78.944306 as well as the street address 2608 Erwin Road # 19a in Durham, North Carolina 27705.
For its online presence, you may visit Cytex Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.